Core One Labs has announced that its wholly-owned subsidiary Vocan Biotechnologies has set in motion steps to expand production of its proprietary biosynthesized psilocybin API (active pharmaceutical ingredient ), for utilization by pharmaceutical manufacturers involved in the development of psychedelic medicines, and delivered to compounding pharmacies for subsequent distribution to licensed physicians for use in authorized patient treatments.
Category Press Release
Published in GlobeNewswire